Breast cancer with high levels of human epidermal growth factor receptor type 2 (HER2) expression (3+ immunohistochemistry status) or HER2 gene amplification (6 or more copies found using in situ hybridization measurements) is clinically defined as HER2-positive (1). This evidence concerns the gene ERBB2 and breast carcinoma.